Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Increases By 16.7%

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 2,800,000 shares, a growth of 16.7% from the March 31st total of 2,400,000 shares. Based on an average daily volume of 1,520,000 shares, the days-to-cover ratio is currently 1.8 days. Currently, 2.5% of the shares of the stock are short sold.

Analysts Set New Price Targets

AMRX has been the subject of several research analyst reports. Piper Sandler raised their price target on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. The Goldman Sachs Group boosted their price objective on Amneal Pharmaceuticals from $5.50 to $6.25 and gave the company a “buy” rating in a report on Monday, March 4th. StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, March 4th. Finally, Barclays upped their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a report on Monday, January 29th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $7.31.

Amneal Pharmaceuticals Stock Up 1.9 %

Shares of AMRX stock opened at $6.05 on Wednesday. The firm has a market capitalization of $1.86 billion, a PE ratio of -19.52 and a beta of 1.33. Amneal Pharmaceuticals has a fifty-two week low of $1.74 and a fifty-two week high of $6.46. The stock’s 50-day simple moving average is $5.72 and its 200-day simple moving average is $5.24. The company has a debt-to-equity ratio of 121.31, a quick ratio of 0.94 and a current ratio of 1.63.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Friday, March 1st. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.07. The business had revenue of $616.98 million for the quarter, compared to the consensus estimate of $630.67 million. Amneal Pharmaceuticals had a positive return on equity of 126.04% and a negative net margin of 3.51%. Equities analysts expect that Amneal Pharmaceuticals will post 0.5 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AMRX. Vanguard Group Inc. lifted its holdings in Amneal Pharmaceuticals by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 13,548,300 shares of the company’s stock worth $57,174,000 after buying an additional 412,599 shares during the last quarter. Rubric Capital Management LP lifted its holdings in shares of Amneal Pharmaceuticals by 98.8% in the 4th quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company’s stock valued at $48,560,000 after purchasing an additional 3,975,500 shares during the last quarter. LSV Asset Management lifted its holdings in shares of Amneal Pharmaceuticals by 10.5% in the 3rd quarter. LSV Asset Management now owns 1,429,300 shares of the company’s stock valued at $6,032,000 after purchasing an additional 136,100 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Amneal Pharmaceuticals by 2.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,329,508 shares of the company’s stock valued at $8,070,000 after purchasing an additional 26,875 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Amneal Pharmaceuticals by 3.4% in the 4th quarter. Teacher Retirement System of Texas now owns 744,752 shares of the company’s stock valued at $4,521,000 after purchasing an additional 24,651 shares during the last quarter. 31.82% of the stock is owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.